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Abstract: We investigated the effects of - and -adrenergic agonists on L-ascorbic 
acid-induced hepatocyte DNA synthesis and proliferation in primary cultures of adult 
rat hepatocytes. In addition, possible signal transduction mechanisms for the effects of 
- and -adrenergic agonists of L-ascorbic acid-induced hepatocyte mitogenesis were 
examined. The results showed that phenylephrine (10
-6
 M) and metaproterenol (10
-6
 
M) alone did not induce hepatocyte DNA synthesis and proliferation. However, when 
combined with L-ascorbic acid (10
-6
 M), these adrenergic agonists potentiated the 
hepatocyte DNA synthesis and proliferation induced by L-ascorbic acid. Western blot 
analysis showed that phenylephrine and metaproterenol did not potentiate L-ascorbic 
acid-induced insulin-like growth factor I receptor tyrosine kinase phosphorylation. In 
contrast, both phenylephrine and metaproterenol significantly potentiated L-ascorbic 
acid-induced extracellular-signal regulated kinase (ERK) phosphorylation within 3 min. 
Moreover, phorbol ester (10
-7
 M) and 8-bromo cAMP (10
-7
 M) also potentiated 
L-ascorbic acid-induced ERK2 phosphorylation. The effects of protein kinase C (PKC) 
and protein kinase A (PKA) activators were antagonized by PKC inhibitor GF109203X 
and PKA inhibitor H-89, respectively. These results suggest that indirect or direct 
activation of PKC and PKA represents a positive regulatory mechanism for 
potentiation of L-ascorbic acid-induced hepatocyte DNA synthesis and proliferation in 
primary cultures of adult rat hepatocytes. 
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1. Introduction 
L-ascorbic acid, also known as vitamin C, is a nutritional supplement essential for 
preventing scurvy. L-ascorbic acid is reversibly oxidized in the body to 
dehydroascorbic acid, which retains full vitamin C activity. Vitamin C is an essential 
nutrient for the biosynthesis of collagen and L-carnitine, and for the conversion of 
dopamine to noradrenaline (Tajima and Pinnell, 1982; Li and Schellhorn, 2007). The 
liver is an important target for the antioxidant effects of vitamin C, and plays a role in 
body vitamin homeostasis. L-ascorbic acid and its derivatives can inhibit or stimulate 
the growth of normal and tumor cells, depending on cell type (Alcain and Buron, 1994; 
Belin et al., 2009; Koh et al., 1998; Ramírez-Farías et al., 2008; Yang et al., 2006). 
However, the cellular mechanisms of these actions are poorly understood.  
The response of adult rat hepatocytes to L-ascorbic acid has not been investigated 
with respect to DNA synthesis and proliferation in vitro. More recently, we reported 
that L-ascorbic acid and its analogs are able to stimulate hepatocyte DNA synthesis 
and proliferation during short-term (e.g., 4 h) culture in primary cultures of adult rat 
hepatocytes by interacting with the insulin-like growth factor (IGF)-I receptor site and 
by activating the receptor tyrosine kinase/ extracellular-signal regulated kinase (ERK) 
pathway (Moteki et al., 2012). ERK1/2, also known as mitogen-activated protein 
kinase (p42/44 MAPK), is now known to be activated in response to a large number of 
mitogenic stimuli, and this enzyme is a key participant in the response to various 
growth factors and cytokines (Ginès et al., 1995; Moriuchi et al., 2001). In a previous 
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report, we showed that activation of extracellular-signal regulated kinase (ERK) 
isoform 2 (ERK2), but not ERK1, is involved in the L-ascorbic acid-induced DNA 
synthesis and proliferation in primary cultures of adult rat hepatocytes.  
On the other hand, catecholamines (e.g., noradrenaline and its analogs) have been 
shown to be involved in the regulation of liver function (e.g., lipid metabolism, 
carbohydrate metabolism and cell growth). There are several types of catecholamine 
receptor, 1- and 2-receptors, that stimulate adenylate cyclase (AC) and increase 
cAMP, while 2-receptors inhibit this activity (Nakamura et al., 1984). 1-receptors are 
involved in phospholipase C activation and subsequent increases in inositolphosphate 
turnover and diacylglycerol production (Kimura and Ogihara, 1997a; Kimura and 
Ogihara, 1998; Dajani et al., 1990).  
We have previously shown that α- and β-adrenergic agonists significantly modulate 
hepatocyte DNA synthesis and proliferation in the presence of growth factors such as 
EGF, HGF, and IGF-I, -II (Kimura and Ogihara, 1997a, 1997b, 1998). However, there 
have been few studies on the adrenergic regulation of ERK1/2 phosphorylation 
induced by L-ascorbic acid in liver parenchymal cells. Therefore, to better understand 
the adrenergic regulation of the L-ascorbic acid-mediated signaling pathway, we 
examined whether 1-, 2- and 2-adrenergic agonists can modulate L-ascorbic 
acid-induced ERK 1/2 isoform phosphorylation in the regulation of hepatocyte 
mitogenesis. The physiological significance of cross-talk between the L-ascorbic 
acid/IGF-I receptor-mediated pathway and 1-, 2-and 2-adrenergic 
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receptor-mediated pathways in regulating hepatocyte proliferation is also discussed. 
 
2. Materials and Methods 
2.1. Animals 
Male Wistar rats (weight, 200-220 g) were obtained from Saitama Experimental 
Animal Co. (Saitama, Japan). Rats were adapted to a light-, humidity- and 
temperature-controlled room over a minimum 3-day period prior to the start of 
experiments. Rats were fed a standard diet and given tap water ad libitum. Animals 
used in this study were handled in accordance with the “Guiding Principles for the 
Care and Use of Laboratory Animals”, as approved by the Ministry of Education, 
Culture, Sports, Science and Technology of Japan and the Guidelines for the Care and 
Use of Laboratory Animals of Josai University. 
 
2.2. Hepatocyte isolation and culture  
The methods of hepatocyte isolation and culture were as described elsewhere 
(Kimura and Ogihara, 1997b). Briefly, rats were anesthetized with an intraperitoneal 
injection of sodium pentobarbital (45 mg/kg). Two-step in situ collagenase perfusion 
was performed to facilitate disaggregation of the adult rat liver, as described previously 
(Seglen, 1975). The viability of hepatocytes consistently exceeded 96%, as determined 
by trypan blue exclusion assay. Unless otherwise indicated, isolated hepatocytes were 
plated onto 6-well collagen-coated plastic culture dishes (35 mm diameter; Iwaki Glass 
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Co., Tokyo, Japan) at a density of 3.3  104 cells/cm2 in minimum essential medium 
containing 5% bovine calf serum and 10-10 M dexamethasone for 3 h in 5% CO2 in air 
(Kimura et al., 2011). The medium was then changed, and cells were cultured in 
serum-free minimum essential medium containing various concentrations of L-ascorbic 
acid with or without adrenergic agonists or specific inhibitors of signal transducers. In 
this study, minimum essential medium was used in place of Williams’ medium E 
because it does not contain L-ascorbic acid, vitamin E or vitamin K. L-ascorbic acid 
was buffered at pH 7.0 with sodium hydroxide and prepared fresh before each 
experiment. 
 
2.3. Measurement of DNA synthesis  
Hepatocyte DNA synthesis was assessed by measuring [
3
H]-thymidine incorporation 
into acid-precipitable materials (Morley and Kingdon, 1972). After an initial 
attachment period of 3 h, hepatocytes were washed twice with serum-free minimum 
essential medium and cultured in medium containing L-ascorbic acid for a further 4 h. 
Cells were pulse-stimulated for 2 h with [
3
H]-thymidine (1.0 Ci/well) at 2 h following 
the addition of L-ascorbic acid. Incorporation of [
3
H]-thymidine into DNA was 
determined as described previously (Kimura and Ogihara, 1997b). Hepatocyte protein 
content was determined using a modified Lowry procedure (Lee and Paxman, 1972) 
with bovine serum albumin as a standard. Data are expressed as dpm/(h･mg cellular 
protein). 
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2.4. Counting number of nuclei 
The number of nuclei rather than the number of cells was counted, as described 
previously, but with minor modifications (Nakamura et al., 1983). Briefly, primary 
cultured hepatocytes were washed twice with 2 ml of Dulbecco’s phosphate-buffered 
saline (pH 7.4). Cells were then lysed by incubation in 0.25 ml of 0.1 M citric acid 
containing 0.1 % Triton X-100 for 30 min at 37C. An equal volume of the nuclear 
suspension was mixed with 0.3% trypan blue in Dulbecco’s phosphate-buffered saline 
(pH 7.4), and nuclei were counted in a hemocytometer. 
 
2.5. Determination of IGF-I receptor tyrosine kinase phosphorylation 
Tyrosine phosphorylation of the IGF-I receptor was identified by Western blotting 
using anti-phosphotyrosine antibody (Li et al., 1994). The phospho-IGF-I receptor 
antibody detects IGF-I receptor only when tyrosine 1161 in the carboxyl-terminal 
region is phosphorylated. This antibody does not cross-react with other tyrosine 
phosphorylated proteins. Briefly, hepatocytes were freshly isolated and seeded at a 
density of 3.3  104 cells/cm2 and cultured in minimal essential medium containing 5% 
newborn bovine serum. The medium was then aspirated and replaced, and cells were 
further cultured in serum-free minimal essential medium with or without L-ascorbic 
acid for various lengths of time. Cultured hepatocytes were washed once with ice-cold 
phosphate-buffered saline (pH 7.4) and then 0.2 ml of lysis buffer (20 mM Tris buffer, 
pH 7.5, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium 
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pyrophosphate, 1 mM sodium orthovanadate, 1 mM -glycerophosphate and 1 mM 
phenylmethylsulfonyl fluoride) was added. Cell lysates were obtained by scraping the 
cells in lysis buffer, followed by sonication for 3 min. Cell lysates were centrifuged 
(3000  g for 3 min at 4C) to remove cellular debris, and were then denatured in 
boiling water for 5 min. For immunoblotting analysis, samples of the supernatant (30 
g/lane) were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) using a 7.5% polyacrylamide resolving gel, transferred to a 
polyvinylidene difluoride (PVDF) membrane, and immunoblotted with 
anti-phosphotyrosine antibody (Li et al., 1994). Blots were developed by enhanced 
chemiluminescence following incubation with horseradish peroxidase 
(HRP)-conjugated secondary antibodies. The tyrosine kinase activity 
(autophosphorylation) of the phosphorylated p95-kDa protein (P-p95-kDa) was 
normalized against that of total p95-kDa protein. Quantification was performed by 
densitometry after development of the membrane with enhanced chemiluminescence 
reagent and exposure to Hyperfilm (Kodak, Japan). Densitometric analysis was 
performed using the NIH image program version 1.6 for Macintosh. Data were 
calculated in arbitrary units and are expressed as means ± S.E.M. The autodiagram is 
representative of three experiments using different cell preparations. 
 
2.6. Measurement of extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
phosphorylation 
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Phosphorylated ERK isoforms (pERK1; P-p44 MAPK and pERK2; P-p42 MAPK) 
were identified by Western blotting analysis using anti-phospho-ERK1/2 monoclonal 
antibody, as previously described (Towbin et al., 1979). Phosphorylated ERK1/2 
phosphorylation was normalized against total ERK1/2 levels. Briefly, cultured 
hepatocytes were washed once with ice-cold phosphate-buffered saline (pH 7.4) and 
0.2 ml of lysis buffer (10 mM Tris-HCl buffer (pH 7.4), 150 mM NaCl, 2 mM EGTA, 
2 mM dithiothreitol, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl 
fluoride, 10 g/ml leupeptin and 10 g/ml aprotinin) was added, after which 
hepatocytes were harvested. After centrifugation at 16,300 × g for 30 min at 4C, cell 
lysates were denatured in boiling water for 5 min. Supernatant samples (30 g of 
protein) were subjected to SDS-PAGE using a 10% acrylamide resolving gel according 
to the method of Laemmli
 
(Laemmli, 1970). After electrophoresis, proteins were 
transferred to Immobilon-P membranes. 
For detection of phosphorylated extracellular-regulated kinase 1 and 2 (pERK1/2), 
membranes were immersed in Tris-buffered saline (pH 7.4) containing 1% bovine 
serum albumin. Membranes were then incubated with an antibody (1 g/ml) against 
pERK1/2 and/or ERK1/2, and were washed as described previously (Towbin et al., 
1979). Antibody binding was visualized by incubation with a horseradish 
peroxidase-conjugated donkey anti-rabbit IgG secondary antibody (1:3000 dilution), 
followed by enhanced chemiluminescence detection (ECL Kit; Amersham, UK). 
Densitometric analysis was performed using NIH Image version 1.68 for Macintosh. 
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Data were calculated in arbitrary units and are expressed as means ± S.E.M. 
Cytosolic protein in hepatocytes was quantified by modification of the Lowry 
procedure using bovine serum albumin as a standard (Lee and Paxman, 1972). 
 
2.7. Materials   
The following reagents were obtained from Sigma-Aldrich (St. Louis, MO): AG538 
(-cyano-(3-methoxy-4-hydroxy-5-iodocinnamoyl)-(3’, 4’-dihydroxyphenyl) ketone), 
aprotinin, 2,4-dideoxyadenosine, and dexamethasone. Rapamycin and PD98059 
(2’-amino-3’-methoxyflavone) were obtained from R & D Systems (Minneapolis, MN). 
8-bromo-cAMP, LY294002 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 
hydrochloride), H-89 (N-[2-(p-bromocinnamylamino) 
ethyl]-5-isoquinolinesulfonamide dihydrochloride), aphidicolin, metaproterenol 
hemisulfate, GF109203X hydrochloride 
(2-[1-(3-Dimethylaminopropyl)-1H-indol-3-yl]-3-(1H-indol-3-yl)maleimide 
hydrochloride, phenylephrine hydrochloride, UK14304 
(5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine), and U-73122 
(1-[6-[[(17)-3-methoxyestra-1,3,5(1016)-trien-17-yl]amin]ohexyl]-1H-pyrrole-2,5-di
one) were obtained from Enzo Life Sciences (Farmingdale, NY). 
12-O-Tetradecanoylphorbol-13-acetate (phorbol ester, TPA) was obtained from 
Research Biochemicals Inc. (Natick, MA). Minimum essential medium and newborn 
calf serum were purchased from Flow Laboratories (Irvine, Scotland). Collagenase 
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(type II) was obtained from Worthington Biochemical Co. (Freehold, NJ). L-ascorbic 
acid was obtained from Wako Pure Chemicals Co. (Osaka, Japan). 
Anti-phospho-ERK1/2 monoclonal antibody, anti-ERK1/2 monoclonal antibody were 
obtained from Cell Signaling Technology (Danvers, MA). Polyclonal anti-IGF-I 
receptor (phospho-Tyr1161) antibody and monoclonal anti-IGF-I receptor antibody 
were obtained from Applied Biochemical Materials Inc. (Richmond, BC). [Methyl-
3
H] 
thymidine (20 Ci/mmol) was purchased from DuPont-New England Nuclear (Boston, 
MA). All other reagents were of analytical grade. 
 
2.8. Statistical Analysis  
 Group comparisons were made by ANOVA for unpaired data followed by post-hoc 
analysis using Dunnett’s multiple comparison tests. Differences of P<0.05 were 
considered to be statistically significant. 
 
3. Results 
3.1. Potentiation of hepatocyte DNA synthesis and proliferation induced by L-ascorbic 
acid by metaproterenol, 8-bromo cAMP, phenylephrine and TPA  
As shown in Figs. 1A and 1B, the 2-adrenegic receptor agonist metaproterenol (10
-6
 
M; Ogihara, 1996), 8-bromo cAMP (10
-7
 M), the 1-adrenegic receptor agonist 
phenylephrine (10
-6
 M; Kajiyama and Ui, 1998) and 
12-O-tetradecanoylphorbol-13-acetate (phorbol ester, TPA; 10
-7
 M; a direct PKC 
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activator; Smith et al., 1983) alone had no effect on hepatocyte DNA synthesis and 
proliferation. However, when combined, both phenylephrine and metaproterenol 
stimulated hepatocyte DNA synthesis (10.0-fold increase from baseline) and 
proliferation (1.4-fold increase from baseline) induced by L-ascorbic acid (10
-6
 M). 
The cell-permeable cAMP analog 8-bromo cAMP, a direct PKA activator (Derubertis 
and Zenser, 1976), and the direct PKC activator TPA also potentiated the L-ascorbic 
acid-induced hepatocyte DNA synthesis and proliferation. The 2-adrenegic receptor 
agonist UK14304 (Remaury et al., 1993) had no effect on the L-ascorbic acid-induced 
hepatocyte mitogenesis. However, the enhancing effects of metaproterenol on 
hepatocyte DNA synthesis and proliferation in the presence of L-ascorbic acid were 
inhibited by UK14304. 
In order to confirm the notion that 10
-6
 M L-ascorbic acid induces hepatocyte DNA 
synthesis and proliferation through receptor tyrosine kinase, PI3 kinase, ERK or the 
mammalian target of rapamycin (mTOR) phosphorylation, we investigated whether the 
IGF-I receptor tyrosine kinase inhibitor AG538 (Blum et al., 2000), the PI3 kinase 
inhibitor LY294002 (Vlahos et al., 1994), the MEK inhibitor PD98059 (Alessi et al., 
1995) and the mTOR inhibitor rapamycin (Chung et al., 1992; Price et al., 1992) are 
able to inhibit L-ascorbic acid-induced hepatocyte DNA synthesis and proliferation in 
the presence or absence of metaproterenol and phenylephrine. Specific inhibitors of 
growth-related signal transducers, such as AG538 (10
-7
 M), LY294002 (10
-7
 M), 
PD98059 (10
-6
 M) and rapamycin (10 ng/ml) almost completely blocked L-ascorbic 
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acid-induced hepatocyte DNA synthesis and proliferation in the presence or absence of 
phenylephrine (10
-6
 M) and metaproterenol (10
-6
 M).  
 
3.2. Effects of metaproterenol, 8-bromo cAMP, phenylephrine and TPA on L-ascorbic 
acid- induced IGF-I receptor tyrosine kinase phosphorylation 
In order to obtain further evidence for the cross-talk between the IGF-I receptor 
mediated-tyrosine kinase/ERK1/2 kinase pathway (ERK1/2 phosphorylation) and the 
1-, 2- and 2-adrenergic receptor-mediated pathway, we examined the effects of 1-, 
2- and 2-adrenergic receptor agonists on IGF-I receptor tyrosine kinase (Tyr1161) 
phosphorylation (p95-kDa protein) induced by L-ascorbic acid in the presence or 
absence of specific inhibitors of growth-related signal transducers. Figure 2 shows that 
L-ascorbic acid (10
-6
 M) caused an increase in tyrosine phosphorylation of a 95-kDa 
protein (IGF-I receptor tyrosine kinase) that peaked at about 3.0-fold (compared with 
control) 3 min after addition. Neither UK14304 (10
-6 
M), metaproterenol (10
-6 
M), 
8-bromo cAMP (10
-7
 M), phenylephrine (10
-6
 M) nor TPA (10
-7
 M) had any effect on 
hepatocyte IGF-I receptor tyrosine kinase phosphorylation in the presence or absence 
of L-ascorbic acid (10
-6
 M) (Fig. 2). When L-ascorbic acid (10
-6
 M) was added in 
combination with AG538 (10
-7
 M), AG538 completely abolished the IGF-I-induced 
increase in receptor autophosphorylation (Tyr1161). In contrast, L-ascorbic 
acid-induced receptor tyrosine kinase phosphorylation was not abolished by LY294002 
(10
-7
 M), PD98059 (10
-6
 M), rapamycin (10 ng/ml) treatment.  
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3.3. Time course and pattern of L-ascorbic acid stimulation of ERK isoform 
phosphorylation, and their potentiation by 2-adrenergic agonist metaproterenol 
Figure 3A shows the typical pattern of phospho-ERK1/2 (pERK1/2) in isolated 
hepatocytes in culture as detected by Western blotting analysis after 1-60 min of 
culture. The phosphorylated ERK2 band (pERK2) was induced after only 1 min, and 
peaked (about 2.5-fold increase) between 3 and 5 min after addition of 10
-6
 M 
L-ascorbic acid (Figs. 3A and 3B). The time course of the effects of a 2-adrenergic 
agonist on ERK1/2 phosphorylation induced by 10
-6
 M L-ascorbic acid was 
investigated using metaproterenol. Stimulation of hepatocytes with L-ascorbic acid in 
the presence of metaproterenol (10
-6
 M) induced a more rapid and significant increase 
in ERK2 phosphorylation than stimulation with L-ascorbic acid alone, reaching a peak 
at 5 min after addition (about 3.5-fold increase from baseline) and rapidly declining to 
basal levels within 30 min (Figs. 3A and 3B). In contrast, metaproterenol alone did not 
significantly stimulate ERK2 phosphorylation (data not shown). In addition, 
metaproterenol in the presence of L-ascorbic acid did not significantly stimulate ERK1 
phosphorylation (Figs. 3A and 3C). These data indicate that metaproterenol (10
-6
 M) 
specifically potentiated L-ascorbic acid-induced ERK2 phosphorylation. 
 
3.4. Effects of specific inhibitors of signal transducers on metaproterenol or 8-bromo 
cAMP-induced ERK1/2 isoform phosphorylation in presence of L-ascorbic acid  
In order to investigate the mechanisms by which the 2-adrenergic receptor/protein 
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kinase A (PKA) pathway potentiates L-ascorbic acid induction of ERK2 
phosphorylation, we examined the effects of metaproterenol (indirect PKA stimulator) 
and the cell-permeable cAMP analog 8-bromo cAMP (direct PKA stimulator) on 
L-ascorbic acid-induced ERK2 phosphorylation (Figs. 4 and 5). The dose-dependent 
potentiation of ERK2 phosphorylation induced by either metaproterenol (Fig. 4) or 
8-bromo cAMP (Fig. 5) was confirmed in the presence of L-ascorbic acid, and was 
almost completely reduced to control levels by AG538 (10
-7
 M) LY294002 (10
-7
 M) 
and PD98059 (10
-6
 M), but not by rapamycin (Figs. 4 and 5). In addition, the 
2-adrenergic agonist UK14304
 
(indirect adenylate cyclase (AC) inhibitor) 
dose-dependently inhibited the metaproterenol-induced potentiation of ERK2 
phosphorylation in the presence of L-ascorbic acid (Fig. 4), but not 8-bromo 
cAMP-induced potentiation (Fig. 5). Furthermore, pretreatment of hepatocytes with the 
direct AC inhibitor 2,4-dideoxyadenosine (10
-6
 M; Holgate et al., 1980) blocked the 
potentiating effect of metaproterenol on the phosphorylation of ERK2 in the presence 
of L-ascorbic acid, but not the effects of 8-bromo cAMP. In contrast, pretreatment of 
hepatocytes with the PKA inhibitor H-89 (10
-7
 M; Zuscik et al., 1994) blocked the 
potentiating effects of metaproterenol and 8-bromo cAMP on the phosphorylation of 
ERK2 in the presence of L-ascorbic acid. UK14304 (10
-7
/10
-6
 M), metaproterenol (10
-6
 
M) or 8-bromo cAMP (10
-7
 M) on its own had no significant effect on the 
phosphorylation of ERK1 or ERK2 (Figs. 4 and 5). 
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3.5. Time course and pattern of L-ascorbic acid stimulation of ERK isoform 
phosphorylation, and their potentiation by 1-adrenergic agonist phenylephrine 
The effects of an 1-adrenergic agonist on the induction of ERK phosphorylation by 
10
-6
 M L-ascorbic acid were investigated using phenylephrine. L-ascorbic acid in the 
presence of phenylephrine (10
-6
 M; an indirect PKC activator) caused a more rapid 
and significant increase in ERK2 phosphorylation than L-ascorbic acid alone. ERK2 
phosphorylation peaked at 3 min (about 3.0-fold increase from baseline) after addition 
and rapidly decreased to basal levels within 30 min (Figs. 6A and 6B). In contrast, 
phenylephrine alone did not significantly stimulate ERK2 phosphorylation (data not 
shown). Phenylephrine (10
-6
 M) in the presence of 10
-6
 M L-ascorbic acid did not 
significantly stimulate ERK1 phosphorylation (Fig. 6C). The present findings indicate 
that phenylephrine potentiates L-ascorbic acid-induced ERK2 phosphorylation. 
 
3.6. Effects of specific inhibitors of signal transducers on phenylephrine- or 
TPA-Induced ERK isoform phosphorylation in presence of L-ascorbic acid 
The effects of an 1-adrenergic agonist on induction of ERK1/2 phosphorylation by 
10
-6
 M L-ascorbic acid were investigated using phenylephrine (10
-6
 M) and a direct 
PKC activator TPA (10
-7
 M). When hepatocytes were stimulated with L-ascorbic acid 
in the presence of phenylephrine (10
-6
 M), or TPA (10
-7
 M), significant potentiation of 
ERK2 phosphorylation was also observed when compared with L-ascorbic acid (10
-6
 
M) alone (Fig. 7). L-ascorbic acid-induced ERK2 phosphorylation in the presence of 
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phenylephrine (10
-6
 M) was also completely blocked by AG538, LY294002 and 
PD98059, but was not blocked by rapamycin. Pretreatment of hepatocytes with the 
phospholipase C (PLC) inhibitor U-73122 (10
-6
 M; Thompson et al., 1991), or the PKC 
inhibitor GF109203X (10
-7
 M;
 
Toullec et al., 1991) blocked the L-ascorbic 
acid-induced phosphorylation of ERK2 in the presence of phenylephrine (10
-6
 M). 
However, pretreatment of hepatocytes with the phospholipase C (PLC) inhibitor 
U-73122 (10
-6
 M) did not block the L-ascorbic acid-induced phosphorylation of ERK2 
in the presence of TPA (10
-7
 M), while the PKC inhibitor GF109203X (10
-7
 M) did. 
Phenylephrine (10
-6
 M), TPA (10
-7
 M), U-73122 (10
-6
 M) or GF109203X alone had no 
significant effects on the phosphorylation of ERK1 or ERK2 (Fig. 7). 
 
4. Discussion 
As shown in Figs. 1A and 1B, we found that both the 1-adrenergic agonist 
phenylephrine and the 2-adrenergic agonist metaproterenol potentiated the hepatocyte 
DNA synthesis and proliferation induced by L-ascorbic acid (10
-6
 M). The potentiating 
effects of phenylephrine and metaproterenol on the L-ascorbic acid-induced hepatocyte 
DNA synthesis and proliferation were almost completely blocked by inhibitors of 
growth-related signal transducers, such as AG538 (10
-7
 M), LY294002 (10
-7
 M), 
PD98059 (10
-6
 M) and rapamycin(10 ng/mL) (Fig. 1). These results suggest that there 
is cross-talk between 1- and 2-adreneric receptor-mediated pathway and IGF-I 
receptor-mediated pathway in the regulation of L-ascorbic acid-induced hepatocyte 
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mitogenesis. In addition, the enhancing effects of 2-adrenergic receptor agonist 
metaproterenol on hepatocyte DNA synthesis and proliferation in the presence of 
L-ascorbic acid were inhibited by 2-adrenergic receptor agonists UK14304 (Fig.1). 
In order to obtain further evidence for the cross-talk between L-ascorbic 
acid-induced IGF-I receptor tyrosine kinase/ERK1/2 kinase activation (ERK1/2 
phosphorylation) and 1- or 2-adrenergic receptor activation, we examined the effects 
of specific inhibitors or activators of growth-related signal transducers and 2- and 
2-adrenergic receptor agonists on IGF-I receptor tyrosine kinase phosphorylation. As 
shown in Figure 2, L-ascorbic acid (10
-6
 M) caused an increase in the IGF-I receptor 
tyrosine phosphorylation of a 95-kDa protein that peaked 3 min after addition. When 
L-ascorbic acid (10
-6
 M) was added in combination with AG538 (10
-7
 M), AG538 
completely abolished the L-ascorbic acid-induced increase in receptor 
autophosphorylation (Tyr1161). In contrast, L-ascorbic acid-induced IGF-I receptor 
tyrosine kinase activation was not abolished by LY294002 (10
-7
 M), PD98059 (10
-6 
M), 
rapamycin (10 ng/ml) treatment. These results indicate that IGF-I receptor tyrosine 
kinase phosphorylation is specifically activated by L-ascorbic acid. 
The present results are also consistent with the reports that ERK1/2 and/or 
mTOR/p70S6K lie downstream of the IGF-I receptor tyrosine kinase in primary 
cultures of adult rat hepatocytes (Moteki et al., 2012; Kimura and Ogihara, 1998; Blum 
et al., 2000; Alexia et al., 2006). As neither the 1-adrenergic receptor agonist 
phenylephrine (10
-6
 M), the diacylglycerol derivative TPA (10
-7
 M), 2-adrenergic 
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receptor agonist metaproterenol (10
-6
 M) nor the cell-permeable cAMP analog 
8-bromo cAMP (10
-7
 M) had any effect on the L-ascorbic acid-induced receptor 
tyrosine kinase phosphorylation (Fig. 2), the results demonstrate that 1- or 
2-adrenergic receptor stimulation do not directly interact with the IGF-I receptor 
stimulation to induce receptor tyrosine kinase phosphorylation.  
It has been reported that ERK plays an important role in the proliferation of 
hepatocytes and other cells induced by growth factors and cytokines (Ginès et al., 
1995; Moriuchi et al., 2001; Alexia et al., 2006; Mebratu and Tesfaigzi, 2009; Katz et 
al., 2007). The proliferative pathway by which L-ascorbic acid activates the IGF-I 
receptor tyrosine kinase (p95 kDa)/ ERK1/2 pathway (MAPK cascade) has been 
described in primary cultures of hepatocytes (Moteki et al., 2012). However, there 
have been very few studies regarding - and -adrenergic receptor-mediated regulation 
of ERK1/2 phosphorylation induced by L-ascorbic acid in primary cultured 
hepatocytes. Therefore, we examined whether 2- and 2-adrenergic agonists modulate 
the L-ascorbic acid-induced changes in ERK2 phosphorylation. 
As shown in Fig. 3, we found that L-ascorbic acid-induced hepatocyte ERK2 
phosphorylation was enhanced by metaproterenol (10
-6
 M), an indirect adenylate 
cyclase (AC) activator, after 5 min of culture (Figs. 3 and 4). In contrast, 
metaproterenol alone had no significant effects on hepatocyte ERK1/2 phosphorylation 
in the absence of L-ascorbic acid (Fig. 4). As shown in a recent report, L-ascorbic acid 
(10
-6
 M) at a concentration that induces hepatocyte DNA synthesis and proliferation 
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rapidly stimulated ERK2, but not ERK1 phosphorylation (Moteki et al., 2012). Fremin 
et al. showed that continued expression of cyclin-D1 in the G0/G1 phase is dependent 
on ERK2 expression by L-ascorbic acid, and that the ablation of ERK1 influences 
neither the proliferation capacity of mice hepatocytes in this regulation, in vivo and in 
vitro, nor the expression pattern of cyclin-D1
 
(Frémin et al., 2007). In agreement with a 
recent report, our data indicate that ERK2 plays a key role in hepatocyte proliferation
 
(Frémin et al., 2007; Frémin et al., 2012). Moreover, L-ascorbic acid induction of 
ERK2 phosphorylation in hepatocytes was almost completely blocked by specific 
inhibitors of signal
 
transducers, such as the IGF-I receptor tyrosine kinase inhibitor 
AG538, PI3 kinase inhibitor LY294002, and the MEK inhibitor PD98059, but not by 
rapamycin (mTOR inhibitor), thus suggesting that mTOR lies downstream of MEK 
(Moteki et al., 2012). 
The enhancing effects of metaproterenol in the presence of L-ascorbic acid were 
inhibited by 2-adrenegic receptor agonist UK14304 (10
-6
 M; indirect AC inhibitor 
which decreases cAMP), 2,4-dideoxyadenosine (10
-6
 M; direct AC inhibitor) and the 
PKA inhibitor H-89, thus suggesting the involvement of PKA in the potentiating 
effects of metaproterenol (Fig. 4). The involvement of PKA in the effects of 
metaproterenol is supported by our previous results, which indicated that 
metaproterenol-induced potentiation of hepatocyte DNA synthesis and proliferation in 
the presence of L-ascorbic acid (10
-6
 M) was completely inhibited by a specific PKA 
inhibitor, H-89 (data not shown). 
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However, the role of the second messenger cAMP in the control of hepatocyte DNA 
synthesis and proliferation remains uncertain (Brønstad et al., 1983; Liu et al., 2005). 
cAMP can either stimulate or inhibit DNA synthesis, depending on culture conditions 
(Kimura and Ogihara, 1998; Brønstad et al., 1983; Liu et al., 2005). We demonstrated 
that the cell-permeable cAMP analog 8-bromo cAMP dose-dependently enhances 
hepatocyte proliferation and ERK2 phosphorylation induced by L-ascorbic acid (Figs. 
1 and 5). These results indicate that there is cross-talk between the 2-adrenergic 
receptor/AC/cAMP pathway and the IGF-I receptor/ERK pathway, which potentiates 
hepatocyte mitogenesis. Because both metaproterenol- and 8-bromo cAMP-induced 
potentiation of ERK2 phosphorylation in the presence of L-ascorbic acid are 
completely inhibited by AG538, LY294002 and PD98059, but not by rapamycin, the 
cross-talk signals mediated by the 2-adrenergic pathway may converge upstream of 
ERK2. 
We examined whether an 1-adrenergic agonist modulates the L-ascorbic 
acid-induced changes in ERK2 phosphorylation. As shown in Figs. 6 and 7, while an 
1-adrenergic agonist phenylephrine alone had no effect on hepatocyte ERK 
phosphorylation in the absence of L-ascorbic acid, L-ascorbic acid-induced ERK2 
phosphorylation was enhanced by phenylephrine. The enhancing effects of 
phenylephrine in the presence of L-ascorbic acid was inhibited by the PKC inhibitor, 
GF109203X (10
-7 
M), thus suggesting the involvement of PKC in the potentiating 
effects of phenylephrine (Fig. 7). The involvement of PKC in the phenylephrine effect 
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is supported by our previous results, indicating that phenylephrine-induced potentiation 
of hepatocyte DNA synthesis and proliferation in the presence of L-ascorbic acid (10
-6
 
M) was completely inhibited by a specific PKC inhibitor, GF109203X (data not 
shown).  
However, the roles of second messengers, such as IP3 and diacylglycerol, in the 
control of hepatocyte DNA synthesis and proliferation remain uncertain (Berridge, 
1993). Phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA; 10
-7
 M), a direct 
activator of PKC, can either directly or indirectly stimulate DNA synthesis depending 
on culture conditions (Kimura and Ogihara, 1998; Ginès et al., 1995; O'Brien et al., 
1979). In addition, 1-adrenergic receptor-mediated signals may interact with upstream 
signal transducers, such as the MEK, raf or ras pathways (Ramirez et al., 1997; Xiao et 
al., 2001), and have a positive influence normal liver growth and liver regeneration 
after partial hepatectomy in vivo (Huh et al., 2004; Beyer et al., 2008). As shown in 
Fig.7, both phenylephrine (indirect PLC/PKC activator)- and TPA-induced potentiation 
of ERK2 phosphorylation in the presence of L-ascorbic acid were completely inhibited 
by AG538, LY294002 and PD98059, but not by rapamycin (Fig. 7). Thus, the 
1-adrenergic receptor/ PLC/ PKC pathway may interact with upstream elements such 
as raf or ras (Ginès et al., 1995; Ramirez et al., 1997; Xiao et al., 2001).  
Based on the present data, a possible scheme for cross-talk between the L-ascorbic 
acid-targeted IGF-I receptor/ERK2 pathway and the 1-adrenergic receptor/PLC/PKC 
pathway and/or 2-adrenergic receptor/AC/PKA pathway is summarized in Fig. 8. The 
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cross-talk signals of the 1- and 2-adrenergic pathway may influence growth-related 
signal transducers such as Ras, Raf and MEK that lie downstream of the IGF-I receptor 
tyrosine kinase, but upstream of ERK (Ginès et al., 1995; Ramirez et al., 1997; Xiao et 
al., 2001; Pollak et al., 2004). More detailed mechanisms of cross-talk between the 
L-ascorbic acid-signaling pathway and the 1-receptor/PLC/PKC and/or 2-adrenergic 
receptor/AC/PKA pathway remain to be explored.  
In conclusion, the present study demonstrates that the cross-talk signals by 
extracellular 1- and 2-adrenoceptor agonists, such as phenylephrine and 
metaproterenol, potentiate L-ascorbic acid-induced ERK2 phosphorylation in primary 
cultured adult rat hepatocytes. Furthermore, the cross-talk signaling may converge 
between downstream of L-ascorbic acid-targeted IGF-I receptor tyrosine kinase, and 
upstream of MEK/ERK and mTOR/p70 S6K (Fig. 8). The present findings support the 
notion that endogenous catecholamine-induced potentiation of hepatocyte DNA 
synthesis and proliferation in the presence of L-ascorbic acid play an important role in 
the activation of the ERK cascade during liver regeneration after partial hepatectomy 
or recovery from liver necrosis caused by toxic chemicals in vivo (Ramírez-Farías et al., 
2008). 
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Figure legends 
Fig. 1. Potentiation by metaproterenol, 8-bormo cAMP, phenylephrine and TPA of 
hepatocyte DNA synthesis and proliferation induced by L-ascorbic acid.  
Freshly isolated hepatocytes were plated at a density of 3.3 × 10
4
 cells/cm
2
 and 
cultured as described in Materials and Methods. After a medium change, hepatocytes 
were cultured with L-ascorbic acid (10
-6
 M), with or without the indicated specific 
inhibitors or activators of signal transducers for 4 h.  
Concentrations were as follows: UK14304, 10
-6
 M; metaproterenol, 10
-6
 M; 8-bromo 
cAMP, 10
-7
 M; phenylephrine, 10
-6
 M; TPA, 10
-7
 M; AG538, 10
-7
 M; LY294002, 10
-7
 
M; PD98059, 10
-6
 M; and rapamycin, 10 ng/ml. 
The rate of hepatocyte DNA synthesis is expressed as dpm/(h･mg cellular protein) 
(A). Hepatocyte proliferation is expressed as the percent increase in total number of 
nuclei, as compared with control culture (B). Results are expressed as means ± S.E.M. 
of three independent experiments. *P<0.05, **P<0.01 vs. respective controls.
 #
P<0.05, 
##
P<0.01 vs. L-ascorbic acid plus metaproterenol (10
-6
 M)-treated controls (L-ascorbic 
acid+metaproterenol). 
$
P<0.05, 
$$
P<0.01 vs. L-ascorbic acid plus phenylephrine (10
-6
 
M)-treated controls (L-ascorbic acid + phenylephrine). 
 
Fig. 2. Effects of metaproterenol, 8-bromo cAMP, phenylephrine and TPA on 
L-ascorbic acid-induced IGF-I receptor tyrosine kinase phosphorylation.  
Freshly isolated hepatocytes were plated at a density of 3.3 × 10
4
 cells/cm
2
 and 
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cultured as described in Materials and Methods. After a medium change, hepatocytes 
were cultured with L-ascorbic acid (10
-6
 M) with or without the indicated specific 
inhibitors or activators of signal transducers for 3 min.  
Concentrations were as follows: UK14304, 10
-6
 M; metaproterenol, 10
-6
 M; 8-bromo 
cAMP, 10
-7
 M; phenylephrine, 10
-6
 M; TPA, 10
-7
 M; AG538, 10
-7
 M; LY294002, 10
-7
 
M; PD98059, 10
-6
 M; and rapamycin, 10 ng/ml. 
Phosphorylated IGF-I receptor tyrosine kinase (P-p95 kDa) (upper bands) and total 
receptor tyrosine kinase protein (p95 kDa) were determined by Western blotting using 
an anti-phospho-IGF-I receptor (Tyr1161) antibody, as described in Materials and 
Methods. Typical Western blot images are indicated on the top of the figure. Results 
are expressed as means ± S.E.M. of three independent experiments. *P < 0.05 vs. 
respective controls.
 #
P<0.05 vs. L-ascorbic acid plus metaproterenol (10
-6
 M)-treated 
controls (L-ascorbic acid + metaproterenol). 
$
P<0.05 vs. L-ascorbic acid plus 
phenylephrine (10
-6
 M)-treated controls (L-ascorbic acid + phenylephrine). 
 
Fig. 3. Time course and patterns of L-ascorbic acid stimulation of ERK isoform 
phosphorylation, and their potentiation by metaproterenol.  
Isolated hepatocytes were cultured for 3 h, and were then washed and incubated in 
either the absence (control; C: medium alone) or presence of 10
-6
 M L-ascorbic acid 
(AA), or 10
-6
 M L-ascorbic acid with 10
-6
 M metaproterenol (A+M) for the indicated 
times (min) at 37C. Phosphorylated ERK isoforms (pERK1/2) were identified by 
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Western blotting using an anti-pERK antibody, as described in Materials and Methods. 
The intensity of the Mr 44-kDa and 42-kDa bands, corresponding to pERK1 and 
pERK2, respectively, was normalized against total ERK (ERK1/2). A: typical Western 
blot images; B: time-course of ERK2 phosphorylation; C: time-course of ERK1 
phosphorylation. Results are expressed as a percentage of the respective control value 
(mean ± SEM of three experiments). *P<0.05, **P<0.01, ***P<0.001 vs. respective 
controls (medium alone). 
 
Fig. 4. Effects of specific inhibitors of signal transducers on metaproterenol-induced 
ERK1/2 isoform phosphorylation in presence of L-ascorbic acid.  
Hepatocytes were stimulated for 5 min with or without L-ascorbic acid (10
-6
 M) in 
the presence or absence of metaproterenol (10
-8
 to 10
-6
 M) and in the presence or 
absence of specific signal transducer inhibitors. Concentrations are as follows: AG538 
(10
-7
 M), LY294002 (10
-7
 M), PD98059 (10
-6
 M), rapamycin (10 ng/ml), H-89 (10
-7
 M) 
or 2,4,-dideoxyadenosine (10
-6
 M) and/or 2-adrenegic receptor agonist UK14304 
(10
-7
,10
-6
 M). Phosphorylated ERK isoforms (pERK1 and pERK2) were determined by 
Western blotting using an anti-phospho-ERK1/2 antibody, as described in the legend to 
Fig. 3. Typical Western blot images are indicated on the top of the figure. Results are 
expressed as a percentage of the respective control value (means ± SEM of three 
experiments). *P<0.05, **P<0.01 vs. respective L-ascorbic acid-treated controls 
(L-ascorbic acid alone), 
#
P<0.05, 
##
P<0.01 vs. L-ascorbic acid plus metaproterenol 
37 
(10
-6
 M)-treated controls. 
 
Fig. 5. Effects of specific inhibitors of signal transducers on 8-bromo cAMP-induced 
ERK isoform phosphorylation in presence of L-ascorbic acid.  
Hepatocytes were stimulated for 5 min with or without L-ascorbic acid (10
-6
 M) in 
the presence or absence of 8-bromo cAMP (10
-9
-10
-7
 M) and in the presence or 
absence of specific signal transducer inhibitors. Concentrations are as follows: AG538 
(10
-7
 M), LY294002 (10
-7
 M), PD98059 (10
-6 
M), rapamycin (10 ng/ml), 
2,4-dideoxyadenosine (10
-6
 M) or H-89 (10
-7
 M) and/or 2-adrenegic receptor agonist 
UK14304 (10
-7
/10
-6
 M). Phosphorylated ERK1/2 isoforms (pERK1/2) were 
determined by Western blotting using an anti-phospho-ERK1/2 antibody, as described 
in the legend to Fig. 3. Typical Western blot images are indicated on the top of the 
figure. Results are expressed as a percentage of the respective control value (mean ± 
SEM of three experiments). *P<0.05, **P<0.01 vs. respective L-ascorbic acid -treated 
controls (L-ascorbic acid alone). 
#
P<0.05, 
##
P<0.01 vs. L-ascorbic acid plus 8-bromo 
cAMP (10
-7
 M)-treated controls. 
 
Fig. 6. Time course and patterns of L-ascorbic acid stimulation of ERK isoform 
phosphorylation, and their potentiation by 1-adrenergic agonist phenylephrine.  
Isolated hepatocytes were cultured for 3 h, then washed and incubated in either the 
absence (control; C: medium alone) or presence of 10
-6
 M L-ascorbic acid (AA) alone, 
38 
or 10
-6
 M L-ascorbic acid with 10
-6
 M phenylephrine (A+P) for the indicated times 
(min) at 37C. Phosphorylated ERK isoforms (pERK1/2) were identified by Western 
blotting using an anti-pERK antibody, as described in the legend to Fig. 3. The 
intensity of the Mr 44-kDa and 42-kDa bands, corresponding to pERK1 and pERK2, 
respectively, was normalized to total ERK (ERK1/2). A: Typical Western blot images; 
B: time-course of ERK2 phosphorylation; C: time-course of ERK1 phosphorylation. 
Results are expressed as a percentage of the respective control value (means ± SEM of 
three experiments). *P<0.05, **P<0.01, ***P<0.001 vs. respective controls (medium 
alone). 
 
Fig. 7. Effects of specific inhibitors of signal transducers on phenylephrine- or 
TPA-induced ERK isoform phosphorylation in presence of L-ascorbic acid.  
Hepatocytes were stimulated for 5 min with or without L-ascorbic acid (10
-6
 M) in 
the presence or absence of phenylephrine (10
-8
-10
-6
 M), and/or TPA (10
-7
 M) and in the 
presence or absence of specific inhibitors of the signal transducers. The concentrations 
are as follows: AG538 (10
-7
 M), LY294002 (10
-7
 M), PD98059 (10
-6 
M), rapamycin 
(10 ng/ml), U-73122 (10
-6
 M) and GF109203X (10
-7
 M). Phosphorylated ERK1/2 
isoforms (pERK1/2) were determined by Western blotting using an 
anti-phospho-ERK1/2 antibody, as described in the legend to Fig. 3. Typical Western 
blot images are indicated on the top of the figure. Results are expressed as a percentage 
of respective control values (means ± SEM of three experiments). *P<0.05, **P<0.01 
39 
vs. respective L-ascorbic acid-treated controls (L-ascorbic acid alone), 
$
P<0.05, 
$$
P<0.01 vs. L-ascorbic acid plus phenylephrine (10
-6
 M)-treated 
controls, 
!
P<0.05, 
!!
P<0.01 vs. L-ascorbic acid plus TPA (10
-7
 M)-treated controls. 
 
Fig. 8. Possible scheme for cross-talk between L-ascorbic acid-targeted IGF-I 
receptor/ERK2 pathway and 1-, 2- or 2-adrenergic receptor-mediated pathways.  
Abbreviations: IGF-I, insulin-like growth factor I; RTK, receptor tyrosine kinase; 
PI3K, phosphatidylinositol-3 kinase; MEK, MAP kinase kinase (upstream signal 
transducer of ERK); ERK2, extracellular-signal regulated kinase 2 (p42 MAPK); 
mTOR, mammalian target of rapamycin; p70S6K, p70 ribosomal protein S6 kinase 
(downstream signal transducer of mTOR); AC, adenylate cyclase; PKA, protein kinase 
A; PIP2, phosphatidylinositol 4,5-biphosphate; PLC, phospholipase C; PKC, protein 
kinase A;→ or ○+ , stimulation;  or ○- , inhibition. 
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